# US 2015/0105280 A1 · Selector based recognition and quantification system and method for multiple analytes in a single analysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105280 A1
- Document ID: US20150105280A1
- Status: Published application
- Kind: A1
- Application number: 14/378,284
- Filed: 2013-01-30
- Published: 2015-04-16
- Earliest claimed: 2010-03-10
- Applicants: Perfinity Biosciences, Inc.
- Inventors: Fred R. Regnier; Nicholas B. Herold; Kevin W. Meyer
- Web page: https://patentgrep.com/patent/US20150105280A1

## CPC

- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- G01N 33/537: with separation of immune complex from unbound antigen or antibody
- G01N 33/6842: {Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A multi-dimensional method is provided for simultaneously analyzing multiple analytes within a sample solution, the method including: adding affinity selectors to a sample solution containing analytes to be measured, the affinity selectors having an affinity for one or more of the analytes within the sample solution; allowing immune complexes to form between the affinity selectors and the analytes; partially or totally resolving the formed immune complexes from non-analyte substances within the sample solution in a first dimension of separation using a selective adsorption technique; dissociating the resolved immune complexes; separating the analytes and the affinity selectors of the dissociated immune complexes from one another in a second dimension of separation using a selective adsorption technique; and resolving the analytes in accordance with their mass-to-charge ratios.

## Claims

### Claim 1

A multi-dimensional method for simultaneously analyzing multiple analytes within a sample solution, the method comprising:
adding affinity selectors to a sample solution containing analytes to be measured, the affinity selectors having an affinity for one or more of the analytes within the sample solution;
allowing immune complexes to form between the affinity selectors and the analytes;
partially or totally resolving the formed immune complexes from non-analyte substances within the sample solution in a first dimension of separation using a selective adsorption technique;
dissociating the resolved immune complexes;
separating the analytes and the affinity selectors of the dissociated immune complexes from one another in a second dimension of separation using a selective adsorption technique; and
resolving the analytes in accordance with their mass-to-charge ratios.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first dimension of separation is performed in column, cartridge, pipette tip, plate, or bead formats.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first dimension of separation is performed on denatured species.

### Claim 4 (depends on 3)

The method of claim 3, wherein the denatured species is formed by reduction and alkylation.

### Claim 5 (depends on 1)

The method of claim 1, wherein enzymatic modification precedes the first dimension of separation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the first dimension of separation is followed by enzymatic digestion prior to the second dimension of separation.

### Claim 7 (depends on 6)

The method of claim 6, wherein the enzymatic digestion is performed using trypsin, lys c, glu c, pepsin, papain, pronase, PNGase F, glucuronidase or a plurality of other enzymes.

### Claim 8 (depends on 1)

The method of claim 1, wherein the second dimension of separation is followed by enzymatic digestion prior to a third dimension of separation.

### Claim 9 (depends on 8)

The method of claim 8, wherein the enzymatic digestion is performed using trypsin, lys c, glu c, pepsin, papain, pronase, PNGase F, glucuronidase or a plurality of other enzymes.

### Claim 10 (depends on 1)

The method in claim 1, wherein two enzymatic modifications are used in tandem with a separation step between them.

### Claim 11 (depends on 1)

The method of claim 1, further comprising the use of an ion mobility separator to separate ionized molecules in a gas phase based on their mobility in a carrier gas.

### Claim 12 (depends on 1)

The method of claim 1, wherein the first and second dimensions of separation comprise at least one of separating according to hydrodynamic volume, targeting a unique structural feature with capture antibodies, targeting a biotinylated feature with immobilized avidin, adsorbing and differentially eluting from a hydrophobic surface, adsorbing and differentially eluting from a charged surface, adsorbing and differentially eluting from an immobilized metal affinity chelator, and adsorbing and differentially eluting from a boronic acid rich surface.

### Claim 13 (depends on 12)

The method of claim 12, wherein the unique structural feature includes at least one of a distinctive natural structural feature of the affinity selectors, a hapten that has been conjugated to the affinity selectors, and an immunogen conjugated to the affinity selectors.

### Claim 14 (depends on 1)

The method of claim 1, wherein the analytes include at least one of an analyte fragment, an analyte derivative, and an analyte isotopomer.

### Claim 15 (depends on 1)

The method of claim 1, wherein the analytes comprise ionized analytes.

### Claim 16 (depends on 1)

The method of claim 1, wherein the affinity selectors include at least one of an antibody and an antibody fragment.

### Claim 17 (depends on 1)

The method of claim 1, wherein the affinity selectors include at least one of an aptamer, a lectin, a phage display protein receptor, a bacterial protein, and an oligonucleotide.

### Claim 18 (depends on 17)

The method of claim 17, wherein the bacterial protein includes at least one of a G protein, an A protein, and a protein that is produced by an organism for targeting a protein from another organism.

### Claim 19 (depends on 17)

The method of claim 17, wherein the oligonucleotide includes at least one of RNA, DNA, and PNA.
